Ancora Founder Peter Seeberger Receives Claude S. Hudson Award in Carbohydrate Chemistry
Read time:
Ancora Pharmaceuticals co-founder and scientific advisor Peter Seeberger has been awarded the “Claude S. Hudson Award in Carbohydrate Chemistry” for his development of an automated carbohydrate synthesizer.
Seeberger accepted the award, along with presenting his paper on the research, CARB 004, at the National Meeting of the American Chemical Society being held in Salt Lake City this week.
Seeberger spoke at the meeting, reporting a major advance in creating carbohydrate-based vaccines. “Instead of years, the carbohydrates that may form the basis of revolutionary new vaccines and drugs to battle diseases such as malaria, HIV, neurological and cardiovascular diseases, now can be precisely synthesized to scale in a fraction of that time,” he said. “Ancora’s automated synthesizer is now one of the fastest methods to create complex carbohydrates.”
Ancora Pharmaceuticals, in collaboration with Prof. Seeberger’s lab at the Max Planck Institute in Berlin, is using the carbohydrate synthesizer to discover and develop over a dozen vaccine candidates targeting some of today’s most serious antibiotic resistant infectious diseases. The most advanced candidate, a malaria vaccine, is in late-stage preclinical development and is headed for clinical trials by 2011.
Seeberger accepted the award, along with presenting his paper on the research, CARB 004, at the National Meeting of the American Chemical Society being held in Salt Lake City this week.
Seeberger spoke at the meeting, reporting a major advance in creating carbohydrate-based vaccines. “Instead of years, the carbohydrates that may form the basis of revolutionary new vaccines and drugs to battle diseases such as malaria, HIV, neurological and cardiovascular diseases, now can be precisely synthesized to scale in a fraction of that time,” he said. “Ancora’s automated synthesizer is now one of the fastest methods to create complex carbohydrates.”
Ancora Pharmaceuticals, in collaboration with Prof. Seeberger’s lab at the Max Planck Institute in Berlin, is using the carbohydrate synthesizer to discover and develop over a dozen vaccine candidates targeting some of today’s most serious antibiotic resistant infectious diseases. The most advanced candidate, a malaria vaccine, is in late-stage preclinical development and is headed for clinical trials by 2011.
Advertisement
